Danish company is battling with Pfizer for US biotech as they seek edge in growing market for weight-loss drugs ...

Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs ...

Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

The battle for obesity drug maker Metsera has escalated into a high-stakes bidding war between two pharmaceutical giants, ...

A bidding war over U. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 ...

NEW YORK () -Novo ​Nordisk CEO Mike ‌Doustdar said during a White House ‌event on Thursday that the company's bid for obesity ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

Pfizer and Novo Nordisk’s bidding war for the weight loss drugmaker Metsera is intensifying. Five updates: 1. Pfizer matched Novo Nordisk’s $10 billion bid for the biotech firm Nov. 5, one day after ...